9 Meters Biopharma, Inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.

CEO

Sandeep Laumas

Employees

Country

United States

ISIN

US45782F1057

Listings

0 Comments

Share your thoughts

FAQ

What is Innovate Biopharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Innovate Biopharmaceuticals stocks are traded under the ticker 2Q3.STU.

What is Innovate Biopharmaceuticals revenue for the last year?▼

Innovate Biopharmaceuticals revenue for the last year amounts to 0 EUR.

What is Innovate Biopharmaceuticals net income for the last year?▼

2Q3.STU net income for the last year is -41.53M EUR.

How many employees does Innovate Biopharmaceuticals have?▼

As of July 15, 2026, the company has 12 employees.

In which sector is Innovate Biopharmaceuticals located?▼

Innovate Biopharmaceuticals operates in the Manufacturing sector.

When did Innovate Biopharmaceuticals complete a stock split?▼

Innovate Biopharmaceuticals has not had any recent stock splits.

Where is Innovate Biopharmaceuticals headquartered?▼

Innovate Biopharmaceuticals is headquartered in Raleigh, United States.